Analyst Jonathan Wolleben from JMP Securities reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) and keeping the price target at $75.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jonathan Wolleben has given his Buy rating due to a combination of factors including promising Phase 2 data from Rhythm Pharmaceuticals’ melanocortin receptor (MCR) agonist. This presents a potential breakthrough in weight loss mechanisms, especially with the ongoing Phase 3 trials for setmelanotide targeting hypothalamic obesity, which are expected to be compelling.
Wolleben also notes the strategic advantage Rhythm Pharmaceuticals holds with its early-stage MC4R candidates, which may offer more flexibility in treating obesity-related conditions. Additionally, the company is exploring other formulations, such as an oral small molecule and a weekly subcutaneous MC4R agonist, which could enhance long-term patient adherence and allow for differentiated pricing strategies. These developments collectively reinforce Wolleben’s confidence in the company’s growth prospects, justifying the Buy rating.
According to TipRanks, Wolleben is a 4-star analyst with an average return of 5.6% and a 41.54% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Larimar Therapeutics, and ProQR.